BeiGene says BGB-3111 'well-tolerated, highly active' in WM
BeiGene presented updated clinical data from an ongoing Phase I study of BTK inhibitor BGB-3111 in patients with Waldenstrom's macroglobulinemia at the 9th International Workshop on Waldenstrom's Macroglobulinemia and Symposium on Advances in Multiple Myeloma in Amsterdam, The Netherlands. The preliminary clinical data demonstrate that BGB-3111 is well-tolerated and highly active in WM, with an overall response rate of 92%, including major response in 83% and very good partial response in 33%, at a median follow-up time of 8.0 months. "The updated data continue to show that BGB-3111 is well-tolerated and highly active in Waldenstrom's macroglobulinemia. The ability to achieve complete and sustained BTK inhibition in both circulating and nodal lymphocytes appears to have translated into very good response frequency and quality, as reflected by the VGPR rate of 33%," commented Constantine Tam, MD, Disease Group Lead for Low Grade Lymphoma and Chronic Lymphocytic Leukemia at Peter MacCallum Cancer Centre, Australia, coordinating principal investigator of the study.